The discussant at ASCO’s NSCLC session said the field would need to “manage expectations” as the drugs do not appear to beat chemotherapy in all-comers. 

Plus deals involving Kissei/JWP, Shionogi/Cilcare, Takeda/Torrent, Genome & Co./Debiopharm, Kaken/J&J, CStone/Ewopharma, MediLink/BioNTech and more.

A missed survival endpoint in the TROPiCS-04 confirmatory trial could spell end to Trodelvy's bladder cancer use, but Gilead is more hopeful of lung cancer success.

The ranks of B7-H3-targeting antibody-drug conjugates under development in China have seen their first dropout, although elsewhere there are two FGFR2b-directed ADCs with first-in-class potential on the horizon. Meanwhile, there have been other discontinuations of KRAS G12C inhibitors and anti-BCMA CAR-T cell therapies in the country, while new players have surfaced in the areas of mRNA cancer vaccines and amyloid-beta-targeting antibodies for Alzheimer’s disease.